Investigating new prognostic crossroads in lung carcinomas; comparing the prognostic potential of vascular endothelial growth factor (VEGF) and its receptors versus endoglin (CD105)

G. Hardavella, E. Arkoumani, P. Galanis, Y. Dalavanga, D. Stefanou, S. Constantopoulos (Ioannina, Athens, Greece)

Source: Annual Congress 2009 - Hot topics in molecular pathology and functional genomics of lung cancer
Session: Hot topics in molecular pathology and functional genomics of lung cancer
Session type: Oral Presentation
Number: 3256
Disease area: Thoracic oncology

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
G. Hardavella, E. Arkoumani, P. Galanis, Y. Dalavanga, D. Stefanou, S. Constantopoulos (Ioannina, Athens, Greece). Investigating new prognostic crossroads in lung carcinomas; comparing the prognostic potential of vascular endothelial growth factor (VEGF) and its receptors versus endoglin (CD105). Eur Respir J 2009; 34: Suppl. 53, 3256

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Vascular endothelial growth factor (VEGF) and its receptors (VEGF-R1-Flt-1, VEGF-R2-KDR/Flk-1) as prognostic indicators in small cell lung carcinomas (SCLC)
Source: Annual Congress 2007 - Diagnosis and prognosis in thoracic oncology
Year: 2007


Expression of vascular endothelial growth factor (VEGF) and its receptors (VEFG-R1-Flt1, VEGF-R2-Flk1) in non small cell lung carcinomas (NSCLC): correlation with lymphangiogenesis and clinical outcome
Source: Annual Congress 2007 - Diagnosis and prognosis in thoracic oncology
Year: 2007


Expression of vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) as a prognostic factor of survival in patients with lung adenocarcinoma
Source: Annual Congress 2008 - Management, quality aspects and prognosis in thoracic oncology
Year: 2008


The clininical value of vascular endothelial growth factor (VEGF) in the development of lung sarcoidosis.
Source: International Congress 2018 – Sarcoidosis: from basic research to patient outcomes
Year: 2018



Increased vascular-endothelial growth factor a (VEGF-A) expression and response to angiogenesis inhibitor erlotinib in non-small-cell lung cancer (NSCLC) – hint for a new predictive marker?
Source: Annual Congress 2007 - Therapeutic approaches in thoracic oncology
Year: 2007


Expression of vascular endothelial growth factor (VEGF) and association with lymphangiogenesis in non small cell (NSCLC) and small cell lung carcinomas (SCLC)
Source: Eur Respir J 2006; 28: Suppl. 50, 386s
Year: 2006

Production of a novel isoform of vascular endothelial growth factor (VEGF) by the normal human lung
Source: Eur Respir J 2006; 28: Suppl. 50, 822s
Year: 2006

Espression of vascular endothelial growth factor (VEGF) and its receptors (VEGF-R1-Flt1, VEGF-R2-Flk1) in non small cell (NSCLC) and small cell lung carcinomas (SCLC). Correlation with clinical outcome
Source: Annual Congress 2008 - Biology in thoracic tumours
Year: 2008


Serum vascular endothelial growth factor; an activation marker and prognostic indicator in sarcoidosis?
Source: Eur Respir J 2005; 26: Suppl. 49, 80s
Year: 2005

Vascular endothelial growth factor (VEGF) is a predictable marker for FEV1 progression in patients with Lymphangiolyomyomatosis (LAM).
Source: International Congress 2019 – Innovative approaches for management and treatment of rare diffuse parenchymal lung diseases
Year: 2019


A role for vascular endothelial growth factor (VEGF) in fibrosis?
Source: Annual Congress 2009 - From emphysema to fibrosis: mechanisms of cellular remodelling in the diseased lung
Year: 2009

The prognostic value of serum epidermal growth factor receptor (EGFR) levels in patients with non-small cell lung cancer
Source: Eur Respir J 2004; 24: Suppl. 48, 674s
Year: 2004

Vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) expression in NSCLC
Source: Eur Respir J 2005; 26: Suppl. 49, 459s
Year: 2005

Pre-operative levels of serum vascular endothelial growth factor A (VEGF-A), C (VEGF-C) and D (VEGF-D) in non-small cell lung cancer (NSCLC). Preliminary report
Source: Annual Congress 2008 - Management, quality aspects and prognosis in thoracic oncology
Year: 2008


Prognostic impact of lymphangiogenesis and lymphatic invasion (CD105 expression) in small cell lung carcinomas
Source: Eur Respir J 2006; 28: Suppl. 50, 386s
Year: 2006

Expression of vascular endothelial-cadherin and vascular endothelial growth factor in non-small cell lung cancer and their clinical significances
Source: Annual Congress 2012 - New aspects of lung cancer biology
Year: 2012

Prognostic significance of epidermal growth factor receptor expression in nonsmall cell lung cancer
Source: Eur Respir J 2002; 20: Suppl. 38, 72s
Year: 2002

Expression of tumor necrosis factor receptor 2 in human non-small cell lung cancer and its role as a potential prognostic biomarker
Source: International Congress 2019 – Biology of lung cancer
Year: 2019


Vascular endothelial growth factor (VEGF) mRNA isoforms in an animal model of acute lung injury
Source: Annual Congress 2003 - Animal models of lung injury: useful or not?
Year: 2003


Elevation of circulating endothelial cell levels in lung cancer – a new prognostic and/or predictive marker?
Source: Annual Congress 2008 - Diagnosis and prognosis in thoracic oncology
Year: 2008